Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1. |
ECCT/25/08/07 | ACCEDE Usability Study USABILITY, ACCEPTABILITY, FEASIBILITY AND COST OF CONTINUOUS GLUCOSE MONITORING BY PERSONS LIVING WITH TYPE 1 DIABETES MELLITUS, HEALTH CARE PROVIDERS AND CAREGIVERS AT THE PAEDIATRIC AND ADOLESCENT ENDOCRINOLOGY CLINIC IN KENYATTA NATIONAL HOSPITAL |
Principal Investigator(s) 1. Prisca Amolo Site(s) in Kenya Kenyatta National Hospital |
View |
2. |
ECCT/25/08/06 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Irene Wambui Inwani Site(s) in Kenya 1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county) 2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county) 3. Kargeno Research & Policy Hub (Kisumu county) 4. KEMRI-CCR-PHRD, Thika site (Kiambu county) |
View |
3. |
ECCT/25/08/04 | MK-8527-010 PrEP A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) |
View |
4. |
ECCT/25/08/03 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Uasin Gishu county) 3. KEMRI-WRP (Kericho county) 4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county) |
View |
5. |
ECCT/25/08/02 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI CMR RCTP (Kisumu county) |
View |